Sec Form 4 Filing - Sirgo Mark A @ BIODELIVERY SCIENCES INTERNATIONAL INC - 2017-09-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sirgo Mark A 2. Issuer Name and Ticker or Trading Symbol BIODELIVERY SCIENCES INTERNATIONAL INC [ BDSI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O BIODELIVERY SCIENCES INTL, INC.,, 4131 PARKLAKE AVENUE, SUITE 225 3. Date of Earliest Transaction (MM/DD/YY) 09/14/2017 (Street) RALEIGH, NC27612 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/14/2017 S 50,000 D $ 2.95 ( 1 ) 1,509,262 D Common Stock 09/15/2017 M 45,421 A $ 1.78 1,554,683 D Common Stock ( 2 ) 09/15/2017 M 33,026 A $ 1.96 1,587,709 D Common Stock 09/15/2017 S 54,833 D $ 2.9 1,532,876 D Common Stock 09/18/2017 S 6,000 D $ 2.85 1,526,876 D Common Stock ( 3 ) 09/19/2017 M 13,661 A $ 2.01 1,540,537 D Common Stock 09/19/2017 S 24,516 D $ 2.75 1,516,022 D Common Stock 09/20/2017 M 25,000 A $ 2.26 1,541,022 D Common Stock ( 4 ) 09/20/2017 M 34,265 A $ 2.43 1,575,286 D Common Stock 09/20/2017 S 65,405 D $ 2.75 ( 5 ) 1,509,881 D Common Stock 09/21/2017 S 619 D $ 2.75 1,509,262 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options $ 1.78 09/15/2017 M 45,421 02/09/2013 02/09/2022 Common Stock 45,421 $ 0 0 D Options ( 2 ) $ 1.96 09/15/2017 M 33,026 02/15/2013 02/15/2022 Common Stock 33,026 $ 0 0 D Options ( 3 ) $ 2.01 09/19/2017 M 13,661 07/24/2009 07/24/2018 Common Stock 6,902 $ 0 0 D Options $ 2.26 09/20/2017 M 25,000 07/21/2011 07/21/2020 Common Stock 25,000 $ 0 0 D Options ( 4 ) $ 2.43 09/20/2017 M 34,265 07/21/2011 07/21/2020 Common Stock 34,265 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sirgo Mark A C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVENUE, SUITE 225 RALEIGH, NC27612 X President and CEO Signatures /s/ Mark A. Sirgo 09/22/2017 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On September 14, 2017, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.95 per share. The highest sale price for the Common Stock was $2.98 per share and the lowest sale price was $2.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 2 )The options exercised were acquired from September 15, 2017 to September 19, 2017. ( 3 )The options exercised were acquired from September 19, 2017 to September 20, 2017. ( 4 )The options exercised were acquired from September 20, 2017 to September 21, 2017. ( 5 )On September 20, 2017, the Reporting Person sold an aggregate of 65,405 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.78 per share and the lowest sale price was $2.75 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks: The Form 4 was due on September 18, 2017 but filed on September 22, 2017 to accommodate multiple connected transactions over several days all on one concise Form 4.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.